Skip to main content
MedPathMedPath Home
Clinical Trials/NCT03131531
NCT03131531
Recruiting
Not Applicable

Bergamo Lymphoid Cancer Registry

A.O. Ospedale Papa Giovanni XXIII1 site in 1 country6,000 target enrollmentMarch 23, 2017
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit
ConditionsHodgkin LymphomaNon Hodgkin LymphomaMyeloma

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Hodgkin Lymphoma
Sponsor
A.O. Ospedale Papa Giovanni XXIII
Enrollment
6000
Locations
1
Primary Endpoint
Overall survival
Status
Recruiting
Last Updated
2 years ago
OverviewInvestigatorsEligibility CriteriaOutcomesSitesSimilar Trials

Overview

Brief Summary

This registry has been established to gain a better understanding of the clinical and biological characteristics and outcome of patients with lymphoid cancer

Detailed Description

Lymphoid cancer including Hodgkin disease, non-Hodgkin lymphomas (NHL) and myeloma, represents the most common hematologic malignancy. Despite the overall prognosis improved in the last 10 years, there are many open issues that need to be addressed, specifically refractoriness to standard treatment, disease recurrence and outcome with new drug in the so called "real world" setting. Since the Hematology and Bone Marrow Transplant Unit at "Ospedale Papa Giovanni XIII" of Bergamo has developed specific tools to collect clinical data thought fully validated electronic charts and biological specimens thanks to a regulatory compliant biobanking program, the aim of this study is to collect clinical and biological information of lymphoid cancer patients. The cohort of patients enrolled will permit to analyze the practice pattern, perform biological correlative studies of great translational potential with relevance to clinical practice.

Registry
clinicaltrials.gov
Start Date
March 23, 2017
End Date
March 23, 2037
Last Updated
2 years ago
Study Type
Observational
Sex
All

Investigators

Sponsor
A.O. Ospedale Papa Giovanni XXIII
Responsible Party
Principal Investigator
Principal Investigator

Rambaldi Alessandro

Prof.

A.O. Ospedale Papa Giovanni XXIII

Eligibility Criteria

Inclusion Criteria

  • •Male or female patients 18 years or older
  • •Written informed consent
  • •Confirmed diagnosis of Hodgkin disease, non-Hodgkin lymphomas or myeloma

Exclusion Criteria

  • •Unconfirmed diagnosis of Hodgkin disease, non-Hodgkin lymphomas or myeloma

Outcomes

Primary Outcomes

Overall survival

Time Frame: 20 years

Analyzed for all patients as time from diagnosis to death as a result of any cause, stratified according to intervention and baseline characteristics

Secondary Outcomes

  • Progression-free survival(20 years)
  • Biological correlative studies(20 years)
  • Disease-free survival(20 years)

Study Sites (1)

Loading locations...

Similar Trials

Completed
Not Applicable
Tumor Registry of Lymphatic NeoplasiaNon-Hodgkin's Lymphoma (NHL)Chronic Lymphocytic Leukemia (CLL)Multiple Myeloma (MM)
NCT00889798iOMEDICO AG3,795
Recruiting
Not Applicable
A Registry for People With T-cell LymphomaT-cell LymphomaNK-Cell LymphomaT-cell Prolymphocytic LeukemiaT-cell Large Granular Lymphocytic LeukemiaChronic Lymphoproliferative Disorder of NK CellsAggressive NK-cell LeukemiaSystemic Epstein-Barr Virus Positive T-Cell Lymphoproliferative Disease of Childhood (Disorder)Systemic Epstein Barr Virus Positive T-Cell Lymphoproliferative Disease of ChildhoodChronic Active EBV Infection of T-and NK-Cell Type, Systemic FormHydroa Vacciniforme-Like Lymphoproliferative DisorderAdult T-cell Leukemia/LymphomaExtranodal NK/T-cell Lymphoma, Nasal TypeEnteropathy-associated T-cell LymphomaMonomorphic Epitheliotropic Intestinal T-Cell LymphomaIntestinal T-Cell Lymphoma, Not Otherwise SpecifiedIndolent T-Cell Lymphoproliferative Disorder of the Gastrointestinal TractHepatosplenic T-cell LymphomaSubcutaneous Panniculitis-Like T-Cell LymphomaMycosis FungoidesSezary SyndromePrimary Cutaneous Anaplastic Large Cell LymphomaPrimary Cutaneous T-cell LymphomaPrimary Cutaneous CD8-Positive Aggressive Epidermotropic T-Cell LymphomaPrimary Cutaneous Acral CD8-Positive T-Cell LymphomaPeripheral T-Cell Lymphoma, Not Otherwise SpecifiedAngioimmunoblastic T-cell LymphomaFollicular T-Cell LymphomaNodal Peripheral T-Cell Lymphoma With TFH PhenotypeAnaplastic Large Cell Lymphoma, ALK-PositiveAnaplastic Large Cell Lymphoma, ALK-negativeBreast Implant-Associated Anaplastic Large Cell Lymphoma
NCT05978141Memorial Sloan Kettering Cancer Center1,000
Active, not recruiting
Not Applicable
Metastatic Tumor Research and Outcomes NetworkMetastatic Spine Tumor
NCT02830451AO Innovation Translation Center960
Recruiting
Not Applicable
Brain Glioma Registry Combining Clinical and Imaging InformationAdult Glioma
NCT02619890Asan Medical Center9,000
Completed
Not Applicable
Tumor Registry Pancreatic CancerPancreas Cancer
NCT02089269iOMEDICO AG2,325